SCHEMBL29660342

SCHEMBL29660342

CCOc1ccc(-c2nc(C(=O)OC(C)(C)C)cs2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.59
RAB9A P51151 5/20 0.51
MAPT P10636 4/20 0.51
NPC1 O15118 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 2/20 0.51
CDC25A P30304 2/20 0.48
CDC25B P30305 2/20 0.48
CDC25C P30307 2/20 0.48
DUSP3 P51452 2/20 0.48
HSP90AA1 P07900 2/20 0.46
MAPK1 P28482 1/20 0.46
TP53 P04637 2/20 0.45
TLR7 Q9NYK1 2/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 1/20 0.44
RECQL P46063 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29660338 0.90 RAB9A (0.49) HPGDSRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL29660366 0.86 RAB9A (0.67) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL22939614 0.85 RAB9A (0.53) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL23578606 0.83 RAB9A (0.57) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL29660311 0.83 ALDH1A1 (0.64) HPGDSRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL29660308 0.82 RAB9A (0.48) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL29660304 0.82 RAB9A (0.54) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL22940139 0.81 RAB9A (0.53) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL22939716 0.81 CDC25A (0.53) HPGDSRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL29660330 0.81 RAB9A (0.50) RAB9AMAPTNPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289698-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-09-15 US disclosed
EP-4003955-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289698-A1 INHIBITORS OF HUMAN ATGL LIPC, LIPG, PNLIP HPGDS 880/4885RAB9A 3552/4885MAPT 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.